Tigecycline. Prospects of its application in the fight against polyresistant strains

Abstract

Despite the advances in antimicrobial therapy, infectious diseases remain one of the leading causes of death worldwide. In most cases, negative results of treatment of bacterial infections are associated with the emergence of pathogens that are resistant to the used antibacterial agents. This whole situation is complicated by the fact that the issue of strain resistance to antibiotics is now becoming more and more threatening. The rate of resistance spread is far outstripping the development of new antimicrobials. For instance, the reports of carbapenem resistance in strains of Klebsiella pneumoniae and other enterobacteria, as well as the rapid spread of carbapenemases among non-fermenting gram-negative bacteria (NFGB), are alarming. The only approved antimicrobial with activity against resistant gram-positive and gram-negative pathogens is tigecycline, the first and only representative of a new class of antibiotics, glycylcyclines. Tigecycline, under the trade name Tygacil® (Wyeth Pharmaceuticals Inc.), was registered in the Russian Federation in October 2009.